NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data
1/3
NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data
Vancouver, British Columbia--(Newsfile Corp. - March 2, 2021) - NeonMind Biosciences Inc. (CSE: NEON)
(OTC Pink: NMBDF) (FSE: 6UF) ("NeonMind") is pleased to announce that it has filed four new provisional
patent applications with the United States Patent and Trademark Office to protect initial data obtained during
NeonMind's preclinical trial.
NeonMind Files Four Additional Provisional Patents on Psilocybin Preclinical Data
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/7646/75809_NM-PR-WEB_.jpg
The provisional patent applications include data derived from NeonMind's initial preclinical trial that began in
November 2020, which examined the potential use of psilocybin as a treatment for weight loss. NeonMind's
proprietary preclinical data shows promise that both low and high dose psilocybin may reduce weight gain and
that the reduction in weight gain can occur in a short period of time.
This patent has also been included to support NeonMind's first filed U.S. provisional patent which has a priority
date of December 4, 2019, and has been converted to a Patent Cooperation Treaty ("PCT") application. By filing
one international patent application under the PCT, applicants can simultaneously seek protection for an
invention in 152 countries.
"We are encouraged with the preliminary results obtained from our preclinical trial," says NeonMind President &
CEO Robert Tessarolo. "Through an expanded portfolio of patent applications, NeonMind is uniquely positioned
to pursue exciting drug development opportunities in the enormously underserved weight management market.
There have been so many solutions developed in the past that have disappointed; a new approach is desperately
needed. We are actively building out our capabilities to execute the critical phases of drug development needed
to support new drug applications to the FDA."
2/3
NeonMind's patent portfolio has potential rights in 152 countries including the United States. It has filed 10 US
provisional patent applications, of which 2 have been converted to PCT applications. The anticipated patent
protection expiry of these pending patents is 2041. NeonMind anticipates that its near term activities will support
additional applications filed later this year.
Compounds now covered by NeonMind's pending patents include:
Psilocin, Psilocybin
4-SH-dimethyltryptamine
1-methylpsilocin
4-fluoro-N,N-dimethyltryptamine
O-acetylpsilocin
4-hydroxy-N-methyl-N-isopropyltryptamine
4-hydroxy-N-methyl-N-ethyltryptamine
LSD, LSA, DMT
Treatments that are covered by NeonMind's pending patents include:
Aiding Weight Loss
Obesity
Compulsive Eating Disorder
Diet Alteration
Reduction of Food Cravings
Decreasing Food Intake
Complications Associated with Obesity
NeonMind owns 100% of all of Its intellectual property except for patents surrounding LSD, LSA and DMT, of
which it owns 80%. Translational Life Sciences Inc. a research collaborator, owns the remaining 20%.
About NeonMind Biosciences Inc.
NeonMind has two divisions, a consumer products division with a focus on medicinal mushroom infused
products, and a pharmaceutical division engaged in drug development of psychedelic compounds. NeonMind's
consumer division currently sells four NeonMind branded coffee products in Canada through NeonMind's direct
to consumer e-commerce platform. In its pharmaceutical division, NeonMind's first drug candidate involves
psilocybin (a complex organic compound found in psychedelic mushrooms) as a treatment for obesity and
related illnesses for which NeonMind is conducting a preclinical trial at the University of British Columbia.
NeonMind's intellectual property includes methods of aiding in weight loss, treating compulsive eating disorder,
treating obesity and complications of obesity by administering psilocybin or other psychedelic compounds.
NeonMind's team includes experts in obesity, psychiatry, psychology, neuroscience, and intellectual property and
executives with experience from leading consumer product and pharmaceutical companies. Jeff B. Smith, one of
NeonMind's directors, brings more than 20 years of experience, including executive roles such as Company
Group Chairman, at Johnson and Johnson Consumer Companies. Rob Tessarolo, NeonMind's President and
CEO, has 25 years of experience in the pharmaceutical industry and has acted as Chief Executive Officer in
several drug development companies, including Cipher Pharmaceuticals Inc. and Mind Medicine (Mindmed)
Inc. Trevor Millar, NeonMind's Chief Psychedelic Officer, was formerly the Chair of MAPS Canada and has
extensive experience in the treatment of substance abuse disorder using psychedelic substances.
For more information on NeonMind, go to www.NeonMindBiosciences.com or buy NeonMind mushroom
infused coffee at www.NeonMind.com.
Rob Tessarolo, President & Chief Executive Officer, NeonMind Biosciences Inc.
Tel: 416-750-3101
3/3
Investor Relations:
Edge Communications
Tel: 1-866-318-6874
Renmark Financial Communications Inc.
Melanie Barbeau
mbarbeau@renmarkfinancial.com
Tel: 416-644-2020 or 212-812-7680
Media Inquiries:
Exvera Communications Inc.
The Canadian Securities Exchange has not reviewed, approved or disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute forward-looking information. These statements
relate to future events or NeonMind's future performance. The use of any of the words "could", "expect",
"believe", "will", "projected","estimated" and similar expressions and statements relating to matters that are not
historical facts are intended to identify forward-looking information and are based on NeonMind's current belief
or assumptions as to the outcome and timing of such future events. Actual future results may differ materially. In
particular, NeonMind's drug development plans, its ability to retain key personnel, and its expectation as to the
development of its intellectual property and other steps in its preclinical and clinical drug development
constitute forward-looking information. Actual results and developments may differ materially from those
contemplated by forward-looking information. Readers are cautioned not to place undue reliance on forward-
looking information. The statements made in this press release are made as of the date hereof. NeonMind
disclaims any intention or obligation to publicly update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as may be expressly required by applicable
securities laws.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/75809